394 related articles for article (PubMed ID: 34061377)
1. Inhibitory effect on SARS-CoV-2 infection of neferine by blocking Ca
Yang Y; Yang P; Huang C; Wu Y; Zhou Z; Wang X; Wang S
J Med Virol; 2021 Oct; 93(10):5825-5832. PubMed ID: 34061377
[TBL] [Abstract][Full Text] [Related]
2. Discovery of Highly Potent Fusion Inhibitors with Potential Pan-Coronavirus Activity That Effectively Inhibit Major COVID-19 Variants of Concern (VOCs) in Pseudovirus-Based Assays.
Curreli F; Ahmed S; Victor SMB; Drelich A; Panda SS; Altieri A; Kurkin AV; Tseng CK; Hillyer CD; Debnath AK
Viruses; 2021 Dec; 14(1):. PubMed ID: 35062273
[TBL] [Abstract][Full Text] [Related]
3. Fangchinoline inhibits SARS-CoV-2 and MERS-CoV entry.
Sadhu S; Dandotiya J; Dalal R; Khatri R; Mykytyn AZ; Batra A; Kaur M; Chandwaskar R; Singh V; Kamboj A; Srivastava M; Mani S; Asthana S; Samal S; Rizvi ZA; Salunke DB; Haagmans BL; Awasthi A
Antiviral Res; 2023 Dec; 220():105743. PubMed ID: 37949319
[TBL] [Abstract][Full Text] [Related]
4. Effective Inhibition of SARS-CoV-2 Entry by Heparin and Enoxaparin Derivatives.
Tandon R; Sharp JS; Zhang F; Pomin VH; Ashpole NM; Mitra D; McCandless MG; Jin W; Liu H; Sharma P; Linhardt RJ
J Virol; 2021 Jan; 95(3):. PubMed ID: 33173010
[TBL] [Abstract][Full Text] [Related]
5. In vitro virucidal activity of Echinaforce®, an Echinacea purpurea preparation, against coronaviruses, including common cold coronavirus 229E and SARS-CoV-2.
Signer J; Jonsdottir HR; Albrich WC; Strasser M; Züst R; Ryter S; Ackermann-Gäumann R; Lenz N; Siegrist D; Suter A; Schoop R; Engler OB
Virol J; 2020 Sep; 17(1):136. PubMed ID: 32907596
[TBL] [Abstract][Full Text] [Related]
6. Sertraline Is an Effective SARS-CoV-2 Entry Inhibitor Targeting the Spike Protein.
Chen Y; Wu Y; Chen S; Zhan Q; Wu D; Yang C; He X; Qiu M; Zhang N; Li Z; Guo Y; Wen M; Lu L; Ma C; Guo J; Xu W; Li X; Li L; Jiang S; Pan X; Liu S; Tan S
J Virol; 2022 Dec; 96(24):e0124522. PubMed ID: 36468859
[TBL] [Abstract][Full Text] [Related]
7. The biogenesis of SARS-CoV-2 spike glycoprotein: multiple targets for host-directed antiviral therapy.
Santopolo S; Riccio A; Santoro MG
Biochem Biophys Res Commun; 2021 Jan; 538():80-87. PubMed ID: 33303190
[TBL] [Abstract][Full Text] [Related]
8. Design of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity.
Zhu Y; Yu D; Yan H; Chong H; He Y
J Virol; 2020 Jul; 94(14):. PubMed ID: 32376627
[TBL] [Abstract][Full Text] [Related]
9. Antiviral drugs targeting endosomal membrane proteins inhibit distant animal and human pathogenic viruses.
Galindo I; Garaigorta U; Lasala F; Cuesta-Geijo MA; Bueno P; Gil C; Delgado R; Gastaminza P; Alonso C
Antiviral Res; 2021 Feb; 186():104990. PubMed ID: 33249093
[TBL] [Abstract][Full Text] [Related]
10. LY6E Restricts Entry of Human Coronaviruses, Including Currently Pandemic SARS-CoV-2.
Zhao X; Zheng S; Chen D; Zheng M; Li X; Li G; Lin H; Chang J; Zeng H; Guo JT
J Virol; 2020 Aug; 94(18):. PubMed ID: 32641482
[TBL] [Abstract][Full Text] [Related]
11. Structural basis of HCoV-19 fusion core and an effective inhibition peptide against virus entry.
Sun H; Li Y; Liu P; Qiao C; Wang X; Wu L; Liu K; Hu Y; Su C; Tan S; Zou S; Wu G; Yan J; Gao GF; Qi J; Wang Q
Emerg Microbes Infect; 2020 Dec; 9(1):1238-1241. PubMed ID: 32482145
[No Abstract] [Full Text] [Related]
12. Ca
Straus MR; Tang T; Lai AL; Flegel A; Bidon M; Freed JH; Daniel S; Whittaker GR
J Virol; 2020 Jun; 94(13):. PubMed ID: 32295925
[TBL] [Abstract][Full Text] [Related]
13. Inhalable nanocatchers for SARS-CoV-2 inhibition.
Zhang H; Zhu W; Jin Q; Pan F; Zhu J; Liu Y; Chen L; Shen J; Yang Y; Chen Q; Liu Z
Proc Natl Acad Sci U S A; 2021 Jul; 118(29):. PubMed ID: 34292870
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of SARS-CoV-2 Virus Entry by the Crude Polysaccharides of Seaweeds and Abalone Viscera In Vitro.
Yim SK; Kim K; Kim IH; Chun SH; Oh TH; Kim JU; Kim JW; Jung WH; Moon HS; Ku BS; Jung KJ
Mar Drugs; 2021 Apr; 19(4):. PubMed ID: 33921174
[TBL] [Abstract][Full Text] [Related]
15. Screening of Botanical Drugs against SARS-CoV-2 Entry Reveals Novel Therapeutic Agents to Treat COVID-19.
Cao J; Liu Y; Zhou M; Dong S; Hou Y; Jia X; Lan X; Zhang Y; Guo J; Xiao G; Wang W
Viruses; 2022 Feb; 14(2):. PubMed ID: 35215943
[TBL] [Abstract][Full Text] [Related]
16. Obatoclax inhibits SARS-CoV-2 entry by altered endosomal acidification and impaired cathepsin and furin activity in vitro.
Mao B; Le-Trilling VTK; Wang K; Mennerich D; Hu J; Zhao Z; Zheng J; Deng Y; Katschinski B; Xu S; Zhang G; Cai X; Hu Y; Wang J; Lu M; Huang A; Tang N; Trilling M; Lin Y
Emerg Microbes Infect; 2022 Dec; 11(1):483-497. PubMed ID: 34989664
[No Abstract] [Full Text] [Related]
17. Cigarette Smoke Stimulates SARS-CoV-2 Internalization by Activating AhR and Increasing ACE2 Expression in Human Gingival Epithelial Cells.
Almeida-da-Silva CLC; Matshik Dakafay H; Liu K; Ojcius DM
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299289
[TBL] [Abstract][Full Text] [Related]
18. Understanding Severe Acute Respiratory Syndrome Coronavirus 2 Replication to Design Efficient Drug Combination Therapies.
Ortega JT; Zambrano JL; Jastrzebska B; Liprandi F; Rangel HR; Pujol FH
Intervirology; 2020; 63(1-6):2-9. PubMed ID: 33099545
[TBL] [Abstract][Full Text] [Related]
19. Human Defensins Inhibit SARS-CoV-2 Infection by Blocking Viral Entry.
Xu C; Wang A; Marin M; Honnen W; Ramasamy S; Porter E; Subbian S; Pinter A; Melikyan GB; Lu W; Chang TL
Viruses; 2021 Jun; 13(7):. PubMed ID: 34206990
[TBL] [Abstract][Full Text] [Related]
20. Characterization of SARS-CoV-2 Variants N501Y.V1 and N501Y.V2 Spike on Viral Infectivity.
Tang H; Gao L; Wu Z; Meng F; Zhao X; Shao Y; Shi X; Qiao S; An J; Du X; Qin FX
Front Cell Infect Microbiol; 2021; 11():720357. PubMed ID: 34722330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
